BioMarin Pharmaceutical Now Covered by Nomura (BMRN)
Stock analysts at Nomura initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a report issued on Wednesday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $75.00 price target on the stock. Nomura’s price target would indicate a potential upside of 6.87% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note to investors on Friday, January 3rd. They now have a $73.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note to investors on Friday, November 29th. Finally, analysts at Piper Jaffray initiated coverage on shares of BioMarin Pharmaceutical in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $87.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $77.13.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, October 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.08. The company had revenue of $136.90 million for the quarter, compared to the consensus estimate of $140.00 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 6.9% on a year-over-year basis.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.